Leveraging Omeprazole PBPK/PD Modeling to Inform Drug-Drug Interactions and Specific Recommendations for Pediatric...

Area of Science:

• Pharmacology
• Pediatric Drug Development
• Computational Modeling

Background:

• Omeprazole is a common gastrointestinal medication, but pediatric use is complicated by drug interactions, metabolic variability, and safety concerns.
• Pediatric omeprazole pharmacokinetics (PK) are influenced by CYP2C19 metabolism and age-dependent enzyme expression, making dosing challenging.
• Understanding age-related PK/PD is crucial for safe and effective pediatric omeprazole use.

Purpose of the Study:

• To develop and validate a physiologically based pharmacokinetic (PBPK) model for omeprazole and its metabolites.
• To predict age-related variations in omeprazole metabolism and response in pediatric populations.
• To integrate PK with a pharmacodynamics (PD) model to assess efficacy based on intragastric pH.

Main Methods:

• Development and validation of a PBPK model for omeprazole and its metabolites.
• Incorporation of competitive and mechanism-based inhibition of CYP2C19 and CYP3A4.
• Linking the PBPK model with a PD model to predict intragastric pH changes.

Main Results:

• The PBPK model accurately predicted omeprazole and metabolite exposure in adults and pediatrics.
• The model successfully accounted for age-dependent metabolic pathways and inhibition.
• The PBPK-PD model demonstrated the impact of age-related physiological changes on proton pump inhibitor efficacy.

Conclusions:

• The PBPK-PD model enables virtual testing of pediatric dosing scenarios, reducing the need for traditional clinical studies.
• This modeling approach provides valuable insights for accurate pediatric dosing recommendations.
• Physiologically based pharmacokinetic (PBPK) modeling shows significant potential for guiding pediatric drug development and optimizing omeprazole therapy.